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Purpose:  Chlamydophila pneumoniae infection in the airways is thought to be associated with the pathogenesis of asthma, especially in non-atopic 
severe asthma with irreversible airway obstruction that may be related to airway remodeling. Here, we investigated whether C. pneumoniae infec-
tion enhances the secretion of critical chemical mediators for airway remodeling, such as VEGF, TGF-b, and TIMP-1, in human bronchial epithelial 
cells (BECs) in a Th2-dominant microenvironment.  Methods:  Human bronchial epithelial cells (BEAS-2B cells) were infected with C. pneumoniae 
strain TW183 and cultured in both a Th1-dominant microenvironment with INF-g and a Th2-dominant microenvironment with IL-4 or IL-13 added to 
the culture medium. The VEGF, TGF-b, and TIMP-1 levels in the culture supernatants were measured using enzyme-linked immunosorbent assays (ELI-
SA). The activation of NF-kB in each experimental condition was determined using an electrophoretic mobility shift assay.  Results:  Chlamydophila 
pneumoniae-infected BECs showed enhanced secretion of VEGF, TGF-b, and TIMP-1 compared with non-infected BECs. The levels of cytokines se-
creted from BECs were increased more when IL-13 was added to the culture medium. C. pneumoniae-infected BECs also showed increased NF-kB 
activation.  Conclusions:  These results suggest that C. pneumoniae may play a role in the pathogenesis of airway remodeling in asthma, revealing 
a Th2-dominant immune response. Further studies are required to clarify the precise mechanism of C. pneumoniae infection in airway remodeling.
Key Words:  Asthma; Chlamydophila pneumoniae; epithelial cells; vascular endothelial growth factor A; tissue inhibitor of metalloproteinases; 
transforming growth factor beta
INTRODUCTION
Chlamydophila pneumoniae is a widespread respiratory patho-
gen that may cause acute and chronic respiratory tract illness.
1,2 
Recently, C. pneumoniae infection has emerged as one of the 
important factors in the pathogenesis of asthma because this 
organism has been reported to be associated with chronic asth-
ma and its severity,
3-5 acute exacerbation,
6,7 and even the devel-
opment of late-onset asthma in both adults and children.
8,9 In 
addition, a striking association between C. pneumoniae infec-
tion and persistent airflow limitation has been suggested in lon-
gitudinal and cross-sectional sero-epidemiologic studies.
10,11
Chlamydophila pneumoniae can infect and then reside and 
replicate in various structural cells including smooth muscle 
cells, fibroblasts, endothelial cells, bronchial epithelial cells 
(BECs), and various immune cells. Infection of various cell types 
with C. pneumoniae induces the increased release of many pro-
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inflammatory chemical mediators, including tumor necrosis 
factor alpha (TNF-a), interleukin (IL)-8, IL-6, and basic fibro-
blast growth factor (bFGF), and upregulates adhesion mole-
cules.
12-14 In addition, a recent study suggested that C. pneu-
moniae-induced inhibition of apoptosis increases the longevity 
of the host cell, enhancing the survival of C. pneumoniae itself.
15 
C. pneumoniae infection can stimulate the production of IL-10, 
which can downregulate the expression of major histocompati-
bility complex class I molecules,
16 and it might partially contrib-
ute to the resistance to apoptosis and persistence of infected 
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cells. Furthermore, we previously demonstrated that C. pneu-
moniae enhanced the proliferation of human peripheral blood 
mononuclear cells and reduced their steroid responsiveness via 
a TNF-a-dependent pathway.
17
Bronchial epithelial cells (BECs) are a first line of defense in 
viral and bacterial infection. Growing evidence suggests that 
epithelial cells actively contribute to the pathogenesis of bron-
chial asthma through the secretion of chemoattractants and 
pro-inflammatory mediators, which play an important role in 
the initiation and perpetuation of airway inflammation. Previ-
ous studies demonstrated that C. pneumoniae can act as a 
warning system for local immune cells, and airway inflamma-
tion can be induced via the C. pneumoniae-induced release of 
various pro-inflammatory cytokines from BECs.
18,19 Recently, 
we demonstrated that C. pneumoniae-infected BECs enhanced 
the secretion of CCL20 and VEGF involved in oxidative stress.
20 
Taken together, these findings suggest that chronic airway C. 
pneumoniae infection could lead to persistent airway inflam-
mation and may be involved in the airway remodeling ob-
served in the asthmatic airway.
Nevertheless, the exact pathophysiological role of C. pneu-
moniae-infected BECs in the processes of airway remodeling in 
asthma remains unclear. This study evaluated the effect of C. 
pneumoniae infection on the secretion of important chemical 
mediators of airway remodeling, such as vascular endothelial 
growth factor (VEGF), transforming growth factor beta (TGF-b), 
and tissue inhibitor of metalloproteinase (TIMP-1) in human 
BECs in a Th2-dominant microenvironment.
MATERIALS AND METHODS
Culture and inoculum preparation of Chlamydophila pneumoniae
Chlamydophila pneumoniae was cultured and prepared as 
described elsewhere.
18,21 In brief, strain TW183 was purchased 
from the American Type Culture Collection (ATCC, Manassas, 
VA, USA) and propagated in HEp-2 cells (ATCC) grown in Ea-
gle’s minimum essential medium (Sigma, St. Louis, MO, USA) 
supplemented with 1% nonessential amino acids, L-glutamine 
(2 mM), 10% fetal bovine serum (FBS), non-essential amino ac-
ids, gentamicin (10 mg/L), vancomycin (50 mg/L), amphoteri-
cin B (2 mg/L), and HEPES buffer solution (GIBCO BRL Life 
Technologies, Grand Island, NY, USA, 10 mM). Confluent mono-
layers were infected with C. pneumoniae by centrifuging (750× 
g, 35°C, 45 minutes) infectious inoculae onto the host cells. The 
supernatant was replaced by antibiotic-free growth medium 
containing cycloheximide (1 mg/L, Sigma). Infected cells were 
cultured in a 37°C, 5% CO2-saturated humidified incubator, 
harvested on day 3, and disrupted by two cycles of freezing and 
thawing and ultrasonification, and similar harvests were pooled. 
Cell debris was removed by centrifugation at 800× g for 10 min-
utes at 4°C. Aliquots diluted with an equal volume of sucrose-
phosphate-glutamate buffer were stored at -80°C until use. 
Preparation of BEAS-2B cells and infection with Chlamydophila 
pneumoniae
The human BEC cell line BEAS-2B was obtained from ATCC 
(CRL-9606). The cells were subcultured in a 1:1 medium mix-
ture of RPMI 1640 and LHC-9 without serum. We used dishes 
and plates coated with vitrogen 100 and prewarmed at 37°C for 
1 hour. The cells were cultured in a 37°C, 5% CO2 saturated hu-
midified incubator. Stored C. pneumoniae suspensions were 
thawed, diluted, and inoculated onto BEAS-2B by centrifuging 
(750× g, 35°C, 45 minutes).
Immunofluorescence analysis of Chlamydophila pneumoniae-
infected BEAS-2B cells
We evaluated the C. pneumoniae infection and determined 
the bacterial titer using an immunofluorescence (IF) assay after 
48 and 72 hours, as previously described.
21 In brief, infected 
cells were fixed with methanol-acetone (1:1) and incubated 
with antibody to major outer membrane protein (mouse IgG3 
anti-C. pneumoniae monoclonal antibody (mAb); Dako, Cam-
bridgeshire, UK), followed by fluorescein isothiocyanate (FITC)-
conjugated secondary antibody (goat F(ab’)2 anti-mouse IgG; 
Sigma). After counting C. pneumoniae inclusions under a fluo-
rescence microscope and correcting for dilution factors, the 
bacterial titers were expressed as inclusion-forming units (IFU/
cell).
Cell proliferation assay
After confirming C. pneumoniae infection with the IF assay, 
we evaluated whether the cellular proliferation after C. pneu-
moniae infection was maintained and determined the proper 
incubation time and titer of C. pneumoniae. BEAS-2B cells were 
grown to confluence in 96-well plates and were infected with ti-
ters of 0, 0.1, 1, and 10 IFU for 96 hours. Then, 10 µL/well of 
WST-1 reagent was added to each sample. After a 1-hour incu-
bation in a humidified atmosphere (37°C, 5% CO2), the optical 
density of the wells was determined by spectrophotometry at a 
wavelength of 440 nm. The analysis was performed 12, 24, 48, 
72, and 96 hours after the initial infection. The results were ex-
pressed as the percentage increase in cellular proliferation cal-
culated based on the colony-forming units of each sample.
Analysis of VEGF, TGF-b, and TIMP-1 production
BEAS-2B cells were infected with C. pneumoniae (1 IFU/cell 
determined in a proliferation assay) by centrifuging and cul-
tured as described above. Cell-culture supernatants were col-
lected and analyzed 24 hours after C. pneumoniae infection, 
and the levels of VEGF, TGF-b, and TIMP-1 were determined 
using commercial enzyme-linked immunosorbent assay (ELI-
SA) kits (R&D Systems, Minneapolis, MN, USA) according to 
the manufacturer’s guidelines. To evaluate the effect of differ-
ent microenvironments on the production of cytokines, we 
added IL-4 (20 ng/mL) or IL-13 (20 ng/mL) for a Th2-dominant Allergy Asthma Immunol Res. 2010 January;2(1):41-47.  doi: 10.4168/aair.2010.2.1.41
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environment and INF-g (20 ng/mL) for a Th1-dominant envi-
ronment to the culture medium 30 minutes before C. pneu-
moniae infection.
Evaluation of NF-kB activation
To investigate whether NF-kB activation is associated with the 
effect of C. pneumoniae infection on BECs, an electrophoretic 
mobility shift assay (EMSA) was performed. First, nuclear pro-
tein was isolated and prepared using a described method.
22 
Briefly, cells were collected with a scraper and washed twice 
with phosphate-buffered saline. Then, the cell pellet was sus-
pended in buffer A (10 mM HEPES pH 7.8, 15 mM KCl, 2 mM 
MgCl2, 1 mM EDTA, 0.5 mM DTT, 1 mM PMSF, 2 µg/mL leu-
peptin) supplemented with 1% Igepal. After a 15-minute incu-
bation at 0°C, the lysed cellular suspension was briefly mixed 
on a vortex and microcentrifuged for 30 seconds at 4°C. After 
removing the supernatant, the cell pellet was resuspended in 
buffer B (20 mM HEPES pH 7.8, 50 mM KCl, 2 mM MgCl2, 1 
mM EDTA, 20% glycerol, 0.5 mM DTT, 1 mM PMSF, 2 µg/mL 
leupeptin) for 30 minutes at 4°C. The cellular suspension was 
microcentrifuged at 14,000 rpm for 30 seconds. Then, the su-
pernatant was collected and stored at -80°C.
The consensus NF-kB oligonucleotide (sense 5’-AGT TGA 
GGG GAC TTT CCC AGG C-3’ , antisense 3’-TCA ACT CCC CTG 
AAA GGG TCC G-5’) was end-labeled with [g
32P]ATP using T4 
polynucleotide kinase. EMSA binding reactions were performed 
by incubating 5 µg of nuclear extract with 1 µg of poly (dI:dC) in 
a binding reaction mixture (100 mM HEPES, pH 7.8, 60 mM KCl, 
1 mM EDTA, 7% glycerol, 1 mM DTT) for 30 minutes at 37°C. For 
the antibody supershift, NF-kB antibodies p50 and p65 were 
added to each reaction mixture and allowed to bind for 1 hour at 
0°C. The reaction mixture was electrophoresed on 6% polyacryl-
amide gels before vacuum drying and exposure to a storage 
phosphor screen for quantification and documentation.
Statistical methods
All data are expressed as the mean±SEM. The comparisons 
were made using the Mann-Whitney U-test. Statistical signifi-
cance was defined as P<0.05.
RESULTS
Identification of C. pneumoniae infection in BECs
To confirm the C. pneumoniae infection in host cells, we iden-
tified inclusion bodies (element body, EB) of C. pneumoniae in 
BEAS-2B cells for 48 hours using an IF assay; most of the cul-
tured cells contained numerous EBs for up to 72 hours (Fig. 
1A). Based on the results of the proliferation assay performed to 
determine the proper incubation time and bacteria titer, the 
cellular proliferation of cells infected with C. pneumonia at a 
dose of 1 IFU/cell increased continuously, beginning 24 hours 
after infection, and reached near-maximal levels 48 hours after 
infection, whereas the cellular proliferation decreased with 
higher titers of bacteria and more than 72 hours after infection 
Fig. 1.  C. pneumoniae strain TW-183 in BEAS-2B cells. (A) BEAS-2B cells grown on cover slips were infected with C. pneumoniae. After 24 hr, cells were fixed with 
methanol, and stained using a fluorescein conjugated, pneumonia IgG-FITC (×200), BEAS-2B cells (red), C. pneumoniae (green). Proliferation effect of BEAS-2B cells 
infected with C. pneumoniae. (B) BEAS-2B cells were infected with C. pneumoniae at 0 (■), 0.1 (▲), 1 (▼), and 10 (♦) inclusion forming unit (IFU)/cell and cell via-
bility measured at different time points post infection (12, 24, 48, 72, and 96 hr). Results shown are representative of three independent experiments.
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(Fig. 1B). Therefore, we decided to use 1 IFU/cell and 24 hours 
after infection as appropriate experimental conditions for fur-
ther analyses.
Enhanced secretion of VEGF, TGF-b, and TIMP-1 in C. pneumoniae-
infected bronchial epithelial cells
Compared with uninfected cells, the levels of VEGF, TGF-b, 
and TIMP-1 in the supernatants of infected BECs were in-
creased significantly. These results were observed not only in 
the Th1- and Th2-dominant microenvironments, but also un-
der control conditions (Fig. 2). IL-13 further enhanced the pro-
duction of VEGF and TGF-b from both C. pneumonia-infected 
and uninfected BECs, whereas treatment with IL-4 and INF-g 
did not have a significant effect on the secretion of those cyto-
kines. By contrast, the secretion of TIMP-1 from both C. pneu-
monia-infected and uninfected BECs was higher with the INF-g 
treatment.
NF-kB activation in C. pneumoniae-infected bronchial epithelial 
cells
As shown in Figure 3A, the nuclear extracts yielded stronger 
bands in comparison to the uninfected cells, exhibiting rela-
tively higher levels of NF-kB DNA-binding activity. When the 
enhanced NF-kB binding was quantified by densitometry, C. 
pneumoniae infection increased the NF-kB binding under Th1 
and Th2 microenvironments. Conversely, INF-g pretreatment 
reduced the NF-kB binding activity in uninfected cells (Fig. 3B).
DISCUSSION
In this study, we demonstrated that C. pneumoniae-infected 
BECs significantly enhanced the secretion of VEGF, TGF-b, and 
TIMP-1, which are thought to be the major cytokines involved 
in airway remodeling. In addition, the levels of these cytokines 
were increased further under a Th2-dominant microenviron-
ment. These results suggest that C. pneumoniae infection in the 
asthmatic airway may be involved in the pathogenesis of air-
way remodeling.
Bronchial asthma is a Th2-dominant inflammatory airway 
disease with variable airway obstruction. In some asthmatics, 
persistent airflow limitation and a decline in lung function have 
been observed and could be one of the critical factors contrib-
uting to severe asthma. It is also thought that structural changes 
Fig. 2.  Effect of C. pneumoniae infection on VEGF, TGF-b, and TIMP-1 secre-
tion from BEAS-2B cells. BEAS-2B cells were incubated for 24 hr with LHC-9/
RPMI containing 20 ng/mL IL-4, IL-13 or IFN-g in absence or presence of C. 
pneumoniae infection. The levels of VEGF (A), TGF-b (B), and TIMP-1 (C) in the 
supernatants were determined by ELISA. Results shown are representative of 
three independent experiments. *P<0.05 compared to C. pneumoniae uninfect-
ed control. 
†P<0.05 compared with control without cytokine treatment.
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in the airways, widely referred to as airway remodeling, are as-
sociated with irreversible fixed airway obstruction. The remod-
eling in the asthmatic airway is characterized by subepithelial 
fibrosis, increased airway smooth muscle mass, hyperplasia of 
mucous glands and goblet cells, angiogenesis, and alterations 
in the extracellular matrix components.
23 Although chronic in-
flammation is thought to be a key factor contributing to airway 
remodeling, the precise mechanisms remain poorly under-
stood.
For decades, studies have suggested a strong association be-
tween viral or bacterial infection and asthma exacerbations, as 
well as chronic persistent asthma. C. pneumoniae is an obligate 
intracellular Gram-negative bacterium that infects humans as a 
respiratory pathogen. Chlamydophila has a biphasic life cycle, 
existing as either an elementary body (EB) or a reticulate body 
(RB). The metabolically inactive extracellular infectious EB is 
internalized by the host cell, where it differentiates into the 
metabolically active RB. Under certain conditions, RBs do not 
re-differentiate directly into EBs, but form interim non-replicat-
ing persistent bodies, allowing the bacterium to maintain a 
chronic latent infection.
24 Many ongoing studies are investigat-
ing the association between C. pneumoniae and the pathogen-
esis of various chronic inflammatory diseases, such as athero-
sclerosis, macular degeneration, and Alzheimer’s disease.
To our knowledge, this is the first study to investigate the po-
tential role of C. pneumoniae infection in enhanced secretion 
of the cytokines associated with airway remodeling by BECs. 
Our results demonstrated that C. pneumoniae-infected BECs 
lead to the enhanced secretion of VEGF, TGF-b, and TIMP-1. 
Although the functions of these cytokines are very diverse, the 
pivotal features of airway remodeling in asthma, such as en-
hanced tissue fibrosis, angiogenesis, and hypertrophy of consti-
tutional cells may be attributed to the increased levels of VEGF, 
TGF-b, and TIMP-1, at least in part. Another study reported that 
C. pneumoniae-infected BECs released more IL-8 and prosta-
glandin E2 and expressed more ICAM-1 in a time-dependent 
manner.
18 It was also suggested that the blocking of bacterial 
adherence reduced the gene expression of IL-8, INF-g, and 
TNF-a in BECs.
19 Collectively, these findings indicate that C. 
pneumonia-infected BECs may play an important role in the 
pathogenesis of asthma through enhanced induction of critical 
chemical mediators.
In this study, C. pneumoniae-infected BECs under a Th2-
dominant microenvironment secreted more VEGF, TGF-b, and 
TIMP-1 than did those under control conditions, especially 
with the addition of IL-13. Considering the possibility of chron-
ic or recurrent airway infection with C. pneumoniae in asthmat-
ic patients, infected epithelial cells could produce various addi-
tional pro-inflammatory cytokines under a pre-existing Th2-
dominant microenvironment. These results are consistent with 
a report in which Th2 cytokines enhanced TGF-b and VEGF 
production.
25 In this context, our results showed that the inter-
action between the Th2 environment and superimposed C. 
pneumoniae infection is more likely to play an important role in 
airway remodeling.
In this study, the production of TIMP-1 was enhanced after 
pretreatment with the Th1-derived cytokine INF-g, although we 
also saw a tendency toward enhanced TIMP-1 secretion with 
IL-13 treatment. Previous studies reported that the levels of 
INF-g in the blood and sputum of asthmatics were increased 
and correlated with asthma severity.
26,27 TIMP-1, which is the 
major inhibitor of matrix metalloproteinase 9 (MMP-9), has fi-
brogenic properties and promotes the growth of fibroblasts and 
myofibroblasts. Some researchers have reported that an excess 
Fig. 3.  NF-kB activity by C. pneumoniae infection in BEAS-2B cells. Changes of NF-kB binding activity using EMSA (A) gel using g32 P-labeled oligonucleotide 
probes for NF-kB. Densitometry of NF-kB specific binding activity (B) depicts the densitometric evaluation of NF-kB DNA-binding activity, normalized to the level of 
standard reaction.
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of TIMP-1 over MMP-9 in the bronchial secretions of asthmatic 
patients is associated with chronic airflow obstruction.
28,29 
Therefore, INF-g-induced TIMP-1 secretion may be involved in 
the pathogenesis of severe asthma with fixed airway obstruc-
tion, although the clinical and pathophysiological implications 
and exact mechanisms are not clear. Unfortunately, we did not 
measure the MMP-9 levels, so it is hard to draw any conclu-
sions regarding the role of TIMP-1 in the association of INF-g 
and C. pneumonia. Further studies should investigate the 
MMP-9 production in C. pneumonia infection and the role of 
INF-g during the production of this enzyme.
NF-kB was activated in C. pneumoniae-infected BECs in our 
study, whereas stimulation with IL-4, IL-13, or INF-g had no 
further effect on the level of NF-kB activation. This increased 
response of NF-kB activation to the C. pneumoniae infection 
was consistent with previous studies of vascular endothelial 
cells and epithelial cells.
9,30 Furthermore, the results of a recent 
study suggested that C. pneumoniae triggers a pro-inflammato-
ry signaling cascade involving p38 MARK-dependent NF-kB 
activation, resulting in subsequent GM-CSF release.
31 Never-
theless, the exact mechanism by which C. pneumoniae infec-
tion induces VEGF, TGF-b, and TIMP-1 secretion is still unclear.
Interest is growing in developing strategies for preventing air-
way remodeling. The search for novel therapeutic agents based 
on a clear understanding of the pathogenesis of airway remod-
eling is also intensifying. In fact, some evidence suggests that 
macrolide antibiotics do have beneficial effect in asthma, al-
though it is not clear whether the benefit is due to the anti-in-
flammatory or antimicrobial effects of these antibiotics. Our 
data provide additional evidence that macrolide antibiotic 
treatment could have beneficial effects on reducing pro-in-
flammatory cytokines and airway remodeling, especially in 
asthmatic patients with chronic C. pneumoniae infection. Fur-
ther work focusing on the identification of chronic infection is 
needed.
In conclusion, our results suggest that C. pneumoniae-infect-
ed BECs may play a role in the pathogenesis of airway remodel-
ing in asthma under a Th2-dominant microenvironment 
through enhanced secretion of various cytokines.
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